• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 14 (2), 2018
  3. 151-163
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Pharmacology

Year: 2018 | Volume: 14 | Issue: 2 | Page No.: 151-163
DOI: 10.3923/ijp.2018.151.163

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 168

Authors


Qingzan Kong

Country: China

Qing Zhu

Country: China

Liqi  Wang

Liqi Wang

LiveDNA: 86.16380

Keywords


  • Statins
  • hypercholesterolemia
  • Bayesian meta-analysis
  • Cochrane collaboration
  • randomized controlled trial
Review Article

Bayesian Meta-Analysis: The Effect of Statins on the Treatment of Hypercholesterolemia

Qingzan Kong, Qing Zhu and Liqi Wang Liqi  Wang's LiveDNA
Statins inhibit cholesterol synthesis by blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver, thereby ameliorating hypercholesterolemia. Thus, to determine statins with the best efficacy, a meta-analysis was performed to compare the effects of statins against hypercholesterolemia. Comprehensive literature searches were established, from Cochrane library, Pubmed, Embase. The studies were performed to randomize controlled trials (RCTs), cohort studies or case-control studies about efficacy of different statin drugs and dose against hypercholesterolemia published between 1997 and 20 February, 2017. Study qualities were assessed according to Cochrane collaboration recommendations. The non-programming software Aggregate Data Drug Information System (ADDIS) (version 1.16.5) was used to perform Bayesian network meta-analysis and compare treatments using the Markov Chain Monte Carlo (MCMC) method. Overall, 28 RCTs studies, including 12855 patients, met the inclusion criteria. Total cholesterol (TC) levels significantly reduced (p<0.05) using 2 mg Pitavastatin (Pit) than those using 20 mg Pravastatin (Pra), 10 mg Simvastatin (Sim) or 10 mg Atorvastatin (Ato). Similarly, triglyceride (TG) levels reduced using 2 mg Pit than those using 20 mg Pra (p<0.05), 10 mg Sim (p<0.05) or 20 mg Sim (p<0.05) and reduced apolipoprotein B (Apo B) levels were observed than those using 10 mg Ato or 20 mg Pra (p<0.05). Rosuvastatin (Ros) significantly reduced TC and TG levels (p<0.05) when administered at 20 and 10 mg Ros treatments ameliorated percentage changes in low-density lipoprotein cholesterol more than the other drugs (p<0.05) and increased high-density lipoprotein cholesterol levels more effectively than 10 mg Ato (p<0.05), 20 mg Pra (p<0.05) or 10 mg Sim (p<0.05). Increases in Apo A1 levels did not differ between treatments (p>0.05). Among the present statin drug regimens, 2 mg Pit and 10 or 20 mg Ros had the highest efficacy against hypercholesterolemia.
PDF Fulltext XML References Citation

How to cite this article

Qingzan Kong, Qing Zhu and Liqi Wang, 2018. Bayesian Meta-Analysis: The Effect of Statins on the Treatment of Hypercholesterolemia. International Journal of Pharmacology, 14: 151-163.

DOI: 10.3923/ijp.2018.151.163

URL: https://scialert.net/abstract/?doi=ijp.2018.151.163

Related Articles

Adverse Effects of Statins
A Comprehensive Review of the Shared Roles of Inflammatory Cytokines in Osteoporosis and Cardiovascular Diseases as Two Common Old People Problem; Actions Toward Development of New Drugs
A Systematic Review on the Relation between use of Statins and Osteoporosis
Moderation of Immunopathological Parameters by Pravastatin in Pasteurella multocida (Pm52) Induced Septicaemic Mice

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved